Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy

Cancer Science

Volumn 98, Issue 11, 2007, Pages 1803-1808

  Suda, Takako ^a   Tsunoda, Takuya ^a   Daigo, Yataro ^a   Nakamura, Yusuke ^a   Tahara, Hideaki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; EPITOPE; GENE PRODUCT; HLA A24 ANTIGEN; LYMPHOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; PROTEIN KINASE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CELL CLONE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EPITOPE MAPPING; ESOPHAGUS CANCER; GENE EXPRESSION; GENE LOCUS; GENE TARGETING; GENETIC SCREENING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LUNG CANCER; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TRANSACTIVATION; UPREGULATION;

AMINO ACID SEQUENCE; ANTIGENS, LY; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL CYCLE PROTEINS; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; ESOPHAGEAL NEOPLASMS; GPI-LINKED PROTEINS; HLA-A24 ANTIGEN; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; PEPTIDES; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RNA-BINDING PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MARKERS, BIOLOGICAL;

EID: 34848851598     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00603.x     Document Type: Article

References (45)

1. Boon T. Tumor antigens recognized by cytotoxic T lymphocytes: Present perspectives for specific immunotherapy. Int J Cancer 1993; 54: 177-80.
2. Boon T, van der Bruggen P. Human tumor antigen recognized by T lymphocytes. J Exp Med 1996; 183: 725-9.
3. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De-Plaen E, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
4. Brichard V, Van Pel A, Wolfel T et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178: 489-95.
5. Kawakami Y, Eliyahu S, Sakaguchi K et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180: 347-52.
6. Shichijo S, Nakao M, Imai Y et al. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998; 187: 277-88.
7. Chen YT, Scanlan MJ, Sahin U et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acd Sci USA 1997; 94: 1914-18.
8. Umano Y, Tsunoda T, Tanaka H, Matsuda K, Yamaue H, Tanimura H. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild type p53. Br J Cancer 2001; 84: 1052-7.
9. Tanaka H, Tsunoda T, Nukaya I et al. Mapping the HLA-A24-restricted T-cell epitope peptide from a tumor-associated antigen HER2/neu: Possible immunotherapy for colorectal carcinomas. Br J Cancer 2001; 84: 94-9.
10. Nukaya I, Yasumoto M, Iwasaki T et al. Identification of HLA-A24 epitope peptide of carcinoembryonic antigen which induces tumor reactive cytotoxic T lymphocyte. Int J Cancer 1999; 80: 92-7.
11. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998; 4: 321-7.
12. Mukherji B, Chakraborty NG, Yamasaki S et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995; 92: 8078-82.
13. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji BH. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996; 56: 2479-83.
14. Okabe H, Satoh S, Kato T et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: Identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001; 61: 2129-37.
15. Lin Y-M, Furukawa Y, Tsunoda T, Yue C-T, Yang K-C, Nakamura Y. Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 2002; 21: 4120-8.
16. Hasegawa S, Furukawa Y, Li M et al. Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23 040 genes. Cancer Res 2002; 62: 7012-17.
17. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000; 103: 311-20.
18. Saito-Hisaminato A, Katagiri T, Kakiuchi S, Nakamura T, Tsunoda T, Nakamura Y. Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray. DNA Res 2002; 9: 35-45
19. Ochi K, Daigo Y, Katagiri T et al. Expression profiles of two types of human knee joint cartilage. J Hum Genet 2003; 48: 177-82.
20. Kikuchi T, Daigo Y, Katagiri T et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003; 22: 2192-205.
21. Tsai V, Southwood S, Sidney J et al. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol 1997; 158: 1796-802.
22. Riddell SR, Elliott M, Lewinsohn DA et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996; 2: 216-23.
23. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-44.
24. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88: 1442-5.
25. Butterfield LH, Koh A, Meng W et al. Generation of human T cell response to an HLA-A2.1 restricted peptide epitope derived from αfetoprotein. Cancer Res 1999; 59: 3134-42.
26. Vissers JL, De Vries IJ, Schreurs MW et al. The renal cell carcinoma associated antigen G250 encodes a human leukocyte antigen HLA-A2.1 restricted epitope recognized by cytotoxic T lymphocyte. Cancer Res 1999; 59: 5554-9.
27. van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC peptide complex stability. J Immunol 1996; 156: 3308-14.
28. Tanaka F, Fujie T, Tahara K et al. Induction of antitumor cytotoxic T lymphocytes with a MAGE 3 encoded synthetic peptide presented by human leukocytes antigen A24. Cancer Res 1997; 57: 4465-8.
29. Fujie T, Tahara K, Tanaka F, Mori M, Takesako K, Akiyoshi T. A MAGE 1 encoded HLA-A24 binding synthetic peptide induces specific anti tumor cytotoxic T lymphocytes. Int J Cancer 1999; 80: 169-72.
30. Kikuchi M, Nakao M, Inoue Y et al. Identification of a SART 1 derived peptide capable of inducing HLA-A24 restricted and tumor specific cytotoxic T lymphocytes. Int J Cancer 1999; 81: 459-66.
31. Oiso M, Eura M, Katsura F et al. A newly identified MAGE3 derived epitope recognized by HLA-A24 restricted cytotoxic T lymphocytes. Int J Cancer 1999; 81: 387-94.
32. Uchida N, Tsunoda T, Wada S, Furukawa Y, Nakamura Y, Tahara H. Ring finger protein (RNF) 43 as a new target for cancer immunotherapy. Clin Cancer Res 2004; 10: 8577-86.
33. Watanabe T, Suda T, Tsunoda T et al. Identification of Immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastro-intestinal and hepatocellular carcinomas. Cancer Sci 2005; 96: 498-506.
34. Suda T, Tsunoda T, Uchida N et al. Identification of secernin 1 (SCRN1) as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray. Cancer Sci 2006; 97: 411-19.
35. Yuan B, Xu Y, Woo JH et al. Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 2006; 12: 405-10.
36. Mills GB, Schmandt R, McGill M et al. Expression of TTK, a novel human protein kinase, is associated with cell proliferation. J Biol Chem 1992; 267: 16 000-6.
37. de Carcer G, de Castro IP, Malumbres M. Targeting cell cycle kinases for cancer therapy. Curr Med Chem 2007; 14: 969-85.
38. de Nooij-van Dalen AG, van Dongen GA, Smeets SJ et al. Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcinoma. Int J Cancer 2003; 103: 768-74.
39. Lee JW, Lee YS, Yoo KH et al. LY-6K gene: A novel molecular marker for human breast cancer. Oncol Rep 2006; 16: 1211-14.
40. Li C, Rock KL, Woda BA, Jiang Z, Fraire AE, Dresser K. IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: An immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol 2007; 20: 242-7.
41. Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: A retrospective study. Lancet Oncol 2006; 7: 556-64.
42. Vikesaa J, Hansen TV, Jonson L et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 2006; 25: 1456-68.
43. Date Y, Kimura A, Kato H, Sasazuki T. DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese. Tissue Antigens 1996; 47: 93-101.
44. Kondo A, Sidney J, Southwood S et al. Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class II T molecules. J Immunol 1995; 155: 4307-12.
45. Kubo RT, Sette A, Grey HM et al. Definition of specific peptide motifs for four major HLA-A alleles. J Immunol 1994; 152: 3913-24.